Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 11, 2008, Pages 3421-3426

  Sergeeva, Maria V ^a   Zhou, Yuefen ^a   Bartkowski, Darian M ^a   Nolan, Thomas G ^a   Norris, Daniel A ^a   Okamoto, Ellen ^a   Kirkovsky, Leo ^a   Kamran, Ruhi ^a   LeBrun, Laurie A ^a   Tsan, Mei ^a   Patel, Rupal ^a   Shah, Amit M ^a   Lardy, Matthew ^a   Gobbi, Alberto ^a   Li, Lian Sheng ^a   Zhao, Jingjing ^a   Bertolini, Thomas ^a   Stankovic, Nebojsa ^a   Sun, Zhongxiang ^a   Murphy, Douglas E ^a   Webber, Stephen E ^a   Dragovich, Peter S ^a   more..

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

5 Hydroxy 3(2H) pyridazinone derivatives; DMPK properties; Hepatitis C virus (HCV); Non nucleoside NS5B inhibitors; Pyridazinones; RNA dependent RNA polymerase (RdRp); Small molecule

Indexed keywords

4 (1',1' DIOXO 1',4' DIHYDRO 1'LAMBDA 6 BENZO[1',2',4]THIADIAZIN 3' YL) 5 HYDROXY 2H PYRIDAZIN 3 ONE DERIVATIVE; NONSTRUCTURAL PROTEIN 5B; NONSTRUCTURAL PROTEIN 5B POLYMERASE INHIBITOR; PROTEIN INHIBITOR; PYRIDAZINONE DERIVATIVE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INHIBITION; DRUG METABOLISM; DRUG SOLUBILITY; HEPATITIS C VIRUS; LIVER MICROSOME; MONKEY; NONHUMAN; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; HAPLORHINI; HEPACIVIRUS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 44149101456     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.005     Document Type: Article

References (26)

1. WHO, Hepatitis C fact Sheet No. 164. Revised October 2000. http://www.who.int/mediacentre/factsheets/fs164/en, (2000).
2. Lauer G.M., and Walker B.D. N. Engl. J. Med. 345 (2001) 41
3. McHutchison J.G. Am. J. Manag. Care 10 (2004) S21
4. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., and Robins R.K. Science 177 (1972) 705
5. Smith R.A., and Kirkpatrick W. Ribavirin, a Broad Spectrum Antiviral Agent Vol. xiii (1980), Academic Press, New York 237
6. De Clercq E. Adv. Virus Res. 42 (1993) 1
7. Hoofnagle J.H., and Seeff L.B. N. Eng. J. Med. 355 (2007) 2444
8. Appel N., Schaller T., Penin F., and Bartenschlager R. J. Biol. Chem. 281 (2006) 9833
9. Koch U., and Narjes F. Infect. Disorders: Drug Targets 6 (2006) 31
10. Condon S.M., LaPorte M.G., and Herbertz T. Curr. Med. Chem. Anti-Infective Agents 4 (2005) 99
11. Zhou Y., Webber S.E., Murphy D.E., Li L.-S., Dragovich P.S., Tran C.V., Sun Z., Ruebsam F., Shah A.M., Tsan M., Showalter R.E., Patel R., Li B., Zhao Q., Han Q., Hermann T., Kissinger C.R., LeBrun L., Sergeeva M.V., and Kirkovsky L. Bioorg. Med. Chem. Lett. 18 (2008) 1413
12. Zhou Y., Li L.-S., Dragovich P.S., Murphy D.E., Tran C.V., Ruebsam F., Webber S.E., Shah A.M., Tsan M., Averill A., Showalter R.E., Patel R., Han Q., Zhao Q., Hermann T., Kissinger C.R., LeBrun L., and Sergeeva M.V. Bioorg. Med. Chem. Lett. 18 (2008) 1419
13. Li L.-S., Zhou Y., Murphy D.E., Stankovic N., Zhao J., Dragovich P.S., Bertolini T., Sun Z., Ayida B., Tran C.V., Ruebsam F., Webber S.E., Shah A.M., Tsan M., Showalter R.E., Patel R., LeBrun L.A., Bartkowski D.M., Nolan T.G., Norris D.A., Kamran R., Brooks J., Sergeeva M.V., Kirkovsky L., Zhao Q., and Kissinger C.R. Bioorg. Med. Chem. Lett. 18 (2008) 3446
14. Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., and Kopple K.D. J. Med. Chem. 45 (2002) 2615
15. Palm K., Stenberg P., Luthman K., and Artursson P. Pharm. Res. 14 (1997) 568
16. 2 groups in control compound 2 since these entities were known to increase metabolic stability (at the expense of anti-NS5B potency).
17. The weak NS5B inhibition activity exhibited by compound 2 prevented its further development as an anti-HCV agent.
18. 16 exploration of this strategy would likely involve compound modifications that increased (rather than reduced) PSA values.
19. Stoch T.R., and Gudmundsson O. Adv. Drug. Del. Rev. 54 (2002) 315
20. Cianchetta G., Singleton R.W., Zhang M., Wildgoose M., Giesing D., Fravolini A., Cruciani G., and Vaz R.J. J. Med. Chem. 48 (2005) 2927
21. -7 where log D (pH 6.0) and PSA values were calculated using ACD/Labs version 10.0 software (Advanced Chemistry Development, Inc., Toronto ON, Canada, www.acdlabs.com, 2006).
22. 1H NMR and LC-MS analysis (≥95% HPLC purity). They are arbitrarily drawn in one of the possible tautomer forms. The synthesis of these compounds was very similar to that described in Ref. 11.
23. 2, 5 mM dithiothreitol, 0.1 g/L).
24. Davies B., and Morris T. Pharm. Res. 10 (1993) 1093
25. We cannot exclude the possibility that compound 1c is a more efficient efflux substrate than 1b.
26. 2).